278 related articles for article (PubMed ID: 22118625)
1. NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines.
Tsofack SP; Garand C; Sereduk C; Chow D; Aziz M; Guay D; Yin HH; Lebel M
Mol Cancer; 2011 Nov; 10():145. PubMed ID: 22118625
[TBL] [Abstract][Full Text] [Related]
2. An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.
Garand C; Guay D; Sereduk C; Chow D; Tsofack SP; Langlois M; Perreault E; Yin HH; Lebel M
Cancer Sci; 2011 Jul; 102(7):1410-7. PubMed ID: 21466612
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1.
Guo Y; Pang Y; Gao X; Zhao M; Zhang X; Zhang H; Xuan B; Wang Y
Cancer Biomark; 2017; 18(1):1-9. PubMed ID: 28035913
[TBL] [Abstract][Full Text] [Related]
4. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
5. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells.
Plasencia C; Martínez-Balibrea E; Martinez-Cardús A; Quinn DI; Abad A; Neamati N
Int J Oncol; 2006 Jul; 29(1):225-35. PubMed ID: 16773204
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA GAPLINC promotes invasion in colorectal cancer by targeting SNAI2 through binding with PSF and NONO.
Yang P; Chen T; Xu Z; Zhu H; Wang J; He Z
Oncotarget; 2016 Jul; 7(27):42183-42194. PubMed ID: 27259250
[TBL] [Abstract][Full Text] [Related]
7. The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y-box-binding protein-1 overexpressing tumor cells.
Guay D; Garand C; Reddy S; Schmutte C; Lebel M
Cancer Sci; 2008 Apr; 99(4):762-9. PubMed ID: 18307537
[TBL] [Abstract][Full Text] [Related]
8. The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures.
Guay D; Evoy AA; Paquet E; Garand C; Bachvarova M; Bachvarov D; Lebel M
Int J Biochem Cell Biol; 2008; 40(11):2492-507. PubMed ID: 18571458
[TBL] [Abstract][Full Text] [Related]
9. FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells.
Ghatak S; Hascall VC; Markwald RR; Misra S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451103
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death.
Ametller E; García-Recio S; Pastor-Arroyo EM; Callejo G; Carbó N; Gascón P; Almendro V
Cancer Biol Ther; 2011 Jan; 11(1):4-13. PubMed ID: 20980803
[TBL] [Abstract][Full Text] [Related]
11. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
[TBL] [Abstract][Full Text] [Related]
12. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.
Chai H; Liu M; Tian R; Li X; Tang H
Acta Biochim Biophys Sin (Shanghai); 2011 Mar; 43(3):217-25. PubMed ID: 21242194
[TBL] [Abstract][Full Text] [Related]
13. The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells.
Pirpour Tazehkand A; Akbarzadeh M; Velaie K; Sadeghi MR; Samadi N
Biomed Pharmacother; 2018 Jul; 103():755-766. PubMed ID: 29684854
[TBL] [Abstract][Full Text] [Related]
14. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
[TBL] [Abstract][Full Text] [Related]
15. siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells.
Montazami N; Kheir Andish M; Majidi J; Yousefi M; Yousefi B; Mohamadnejad L; Shanebandi D; Estiar MA; Khaze V; Mansoori B; Baghbani E; Baradaran B
Cell Mol Biol (Noisy-le-grand); 2015 May; 61(2):98-103. PubMed ID: 26025411
[TBL] [Abstract][Full Text] [Related]
16. The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.
Lin X; Stenvang J; Rasmussen MH; Zhu S; Jensen NF; Tarpgaard LS; Yang G; Belling K; Andersen CL; Li J; Bolund L; Brünner N
BMC Genomics; 2015 May; 16(1):404. PubMed ID: 25997618
[TBL] [Abstract][Full Text] [Related]
17. IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer.
de Silva HC; Lin MZ; Phillips L; Martin JL; Baxter RC
Cell Mol Life Sci; 2019 May; 76(10):2015-2030. PubMed ID: 30725116
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
[TBL] [Abstract][Full Text] [Related]
19. p54nrb/NONO regulates cyclic AMP-dependent glucocorticoid production by modulating phosphodiesterase mRNA splicing and degradation.
Lu JY; Sewer MB
Mol Cell Biol; 2015 Apr; 35(7):1223-37. PubMed ID: 25605330
[TBL] [Abstract][Full Text] [Related]
20. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
